Emerging drugs for moderate-to-severe psoriasis.
Psoriasis is a chronic, incurable, disabling skin disease characterised by red, scaly plaques. Approximately 23% of psoriasis patients also have an accompanying arthritis that can become debilitating. Psoriasis has a stigmatising effect on its victims, who often feel socially isolated. Although the exact aetiology of psoriasis is still unknown, it is clearly an immune-mediated disease. Traditional therapies for psoriasis include topical drugs, such as corticosteroids, retinoids and vitamin D3 analogues; systemic drugs, such as methotrexate, ciclosporin and retinoids; and phototherapy. These mainstays of treatment are efficacious for the treatment of severe disease; however, most are associated with toxicities or are inconvenient. Recent advances in biotechnology have produced new pharmaceuticals that interfere with immune responses thought to be involved in the pathogenesis of psoriasis and other inflammatory diseases. The immunobiologicals, one new family of drugs, consist of monoclonal antibodies and fusion proteins. Many have demonstrated efficacy in treating psoriasis. Some appear to offer safety benefits over traditional therapies; further monitoring and surveillance of these agents is required to adequately establish safety profiles. This article discusses existing and emerging treatments for moderate-to-severe psoriasis.
Magliocco
Melissa A
MA
UMDNJ-Robert Wood Johnson Medical School, Clinical Research Center, 51 French Street, New Brunswick, NJ 08901-0019, USA. maglioma@umdnj.edu
D002986:Clinical Trials as Topic / Q000639:trends; D015507:Drugs, Investigational / Q000627:therapeutic use*; D006801:Humans; D007155:Immunologic Factors / Q000276:immunology / Q000627:therapeutic use; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000276:immunology
D015507:Drugs, Investigational; D007155:Immunologic Factors; D014409:Tumor Necrosis Factor-alpha